Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Menlo Micro is the developer of the Ideal Switch, an electromechanical switch technology used to switch AC/DC and RF. The Ideal Switch can handle high temperatures and high-stress conditions and help in battery management, home automation, and instrumentation that enable clients to work with advanced products and deliver efficient outcomes using high power. Menlo Micro was founded in 2016 and is headquartered in Irvine, California.
Energy Vault SA offers an energy storage technology utilizing fundamental principles of science to deliver a storage solution that's as compassionate to the planet as it is efficient to build and operate. The Energy Vault solution utilizes the same fundamentals of physics and kinetic energy as pumped hydro but replaces the water with custom made cylindrical blocks utilizing an extremely innovative use of low-cost materials. The system is modular and can be designed with a capacity of between 10 and 35MWh and a power output of up to 5MW. The system has been designed for a 30+ year life with no degradation in storage capacity.
ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support. It connects the nursing community with opportunities and each other to build a supportive and thriving network.
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.
Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient’s disease, condition, or symptoms.
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assist individuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need.
GoPuff delivers products like over-the-counter medicine, baby food, and alcohol. Across America, GoPuff is known for satiating late-night cravings for Ben and Jerry’s ice cream, Doritos, Red Bull, and, in select markets, White Claw and rescuing those in need of diapers, condoms, and cleaning products. GoPuff allows users the joy of browsing the shelves without the hassle of going to the store. It takes seconds to navigate the app and minutes for Gopuff’s Driver-Partners to deliver the customer’s needs and wants. The company was founded in 2013 by Yakir Gola and Rafael Ilishayev, two Drexel University students with a minivan and a vision to make everyday life a little easier.
GOAT is a global marketplace specializing in authentic sneakers, apparel, and accessories from contemporary luxury brands. Founded in 2015 by Daishin Sugano and Eddy Lu in Culver City, California, the platform provides users with access to exclusive drops, the ability to make offers on desired items, and a selection that spans from iconic styles of the past to future classics. GOAT operates both online and through thirteen physical locations across the United States, Asia, and Europe, including distribution and authentication centers that serve 170 international markets. The platform features over 350 brands and has built a community of over 20 million members across 164 countries. By leveraging innovative technology, GOAT has transformed sneaker commerce, ensuring the authenticity of products while bridging the gap between primary and resale markets. Strategic backing from investors such as Foot Locker and prominent venture capital firms underscores its significant presence in the fashion and sneaker industries.
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
Forter is a company that delivers real-time, completely automated, fraud prevention solutions for online merchants. It creates a completely fraud-free environment for the retailers through which they have the ability to make decisions that are solely based on what is good for their business. The company’s system is designed to be consumer-centric, blocking fraud with accuracy, and at the same time enabling growth by increasing approvals and ensuring a better customer experience.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company (MLSoC) that develops machine learning technology to deliver a software-centric platform. With push-button performance, they enable effortless ML deployment and scaling at the embedded edge by allowing customers to address any computer vision problem while achieving 10x better performance at the lowest power. The company's hardware-to-software stack flexibly adjusts to any framework, network, model, sensor, or modality all in one platform. Edge ML applications that run completely on the SiMa.ai MLSoC see an increase in performance and energy efficiency and bring higher fidelity intelligence to ML use cases spanning computer vision to generative AI.
Stem brings and optimizes energy consumption to business through its distributed storage technology. Since 2009, Stem has been analyzing how various types of businesses use electricity and how they are charged for it. The company uses this information to design a solution that protects companies from unnecessarily high electricity costs without requiring any changes to the way they run their businesses. Stem combines big data, predictive analytics, and energy storage to reduce electric costs for businesses and in aggregate, deliver services to the grid.
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
HawkEye 360 is a data analytics company that develops space-based radio frequency mapping. The company operates a commercial satellite constellation to identify, process, and geolocate a broad set of RF signals. Its products include maritime domain awareness and spectrum mapping and monitoring.
Private Equity Round in 2021
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Flywire is a payments enablement and software company. It combines its proprietary payments network, next-gen payments platform, and vertical-specific software to deliver the most important and complex payments for clients and their customers. Flywire supports 4,000 + clients with diverse payment methods in more than 140 currencies across 240 countries and territories around the world. Flywire is headquartered in Boston, MA, USA with global offices.
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders. It creates human-relevant systems to accurately replicate the biology of organ systems and diseases for use throughout drug discovery and development. They work strategically in partnerships with pharmaceutical, biotechnology, and medical device companies. It generates meaningful human response data to increase confidence in decision-making, reduce the risk of costly failures, and identify efficacious therapies.
MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products to improve muscle health and performance.
Private Equity Round in 2020
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.
Flame Biosciences is a clinical-stage company focused on the discovery, development, and commercialization of transformative therapies for cancer and other inflammatory diseases.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient’s disease, condition, or symptoms.
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.
Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.
Flywire is a payments enablement and software company. It combines its proprietary payments network, next-gen payments platform, and vertical-specific software to deliver the most important and complex payments for clients and their customers. Flywire supports 4,000 + clients with diverse payment methods in more than 140 currencies across 240 countries and territories around the world. Flywire is headquartered in Boston, MA, USA with global offices.
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.
Private Equity Round in 2018
Tanium is a security and systems management platform that allows real-time data collection at an enterprise scale. It provides enterprise and government organizations with tools to secure, control, and manage millions of endpoints across the enterprise within seconds. The platform allows security and IT operations teams to get access to visibility and accurate information on the state of endpoints at all times to protect against modern-day disruptions and realize new levels of business resilience. Tanium was founded by David Hindawi and Orion Hindawi in 2007 and is headquartered in Kirkland, Washington, United States.
MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products to improve muscle health and performance.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
Welldoc develops technology solutions to support chronic disease management. They work with leaders across the healthcare, life science, and medical device industries to ensure the solutions they develop scale and integrate into their existing workflows and systems. The Welldoc platform offers support for multiple chronic conditions, ecosystem solutions, and artificial intelligence.
Vapotherm is specializing in the development, manufacture, and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs, and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification. Vapotherm high velocity therapy has been shown to provide proven, comfortable respiratory support without the use of a mask. High Velocity Therapy is a method of rethinking ventilatory support while keeping patient comfort and compliance in mind.
Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.
Vapotherm is specializing in the development, manufacture, and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs, and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification. Vapotherm high velocity therapy has been shown to provide proven, comfortable respiratory support without the use of a mask. High Velocity Therapy is a method of rethinking ventilatory support while keeping patient comfort and compliance in mind.
AAA is an innovative medicines company focused on the development of targeted radioligand therapies and precision imaging radioligands.
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.
MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products to improve muscle health and performance.
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Their services include gene therapy, biotechnology, rare diseases, ophthalmology, and retina.
EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.
Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs. Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines in humans. We think it’s time companion animals reaped the benefits of human medical progress in this field. Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications. To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards. Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.
Vapotherm is specializing in the development, manufacture, and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs, and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification. Vapotherm high velocity therapy has been shown to provide proven, comfortable respiratory support without the use of a mask. High Velocity Therapy is a method of rethinking ventilatory support while keeping patient comfort and compliance in mind.
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Private Equity Round in 2013
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
Private Equity Round in 2011
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.